NasdaqGS:PHVSPharmaceuticals
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst
Pharvaris (PHVS) is back in focus after announcing that eight deucrictibant abstracts, including Phase 3 and long term safety data, have been accepted for presentation at the 2026 European Academy of Allergy and Clinical Immunology Congress.
See our latest analysis for Pharvaris.
At a share price of US$31.09, Pharvaris has seen a 17.4% year to date share price return and an 85.3% total shareholder return over one year. The 1 day move was a modest pullback that contrasts with stronger 90 day...